Manufacturer record
Life Max Cancer Laboratories: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
37 batches manufactured by Life Max Cancer Laboratories (Uttarakhand) were declared Not of Standard Quality between November 2019 and February 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: LMT240480, Bisacodyl GR Tablets IP 5MG (exp Mar 2026). SDTL, Assam (state lab) found it not of standard quality: The sample does not conform to I.P.w.r.t. the test for Dissolution and Assay. Listed in the February 2026 alert.
Records by type
37 records linked to Life Max Cancer Laboratories in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
0Banned or prohibited
0Recalled or suspended
37Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
37
NSQ batches since 2019
14
Products affected
Assay
Most common failure
Feb 2026
Latest alert
Flagged batches per year
2019 · 12023 · 12024 · 222025 · 122026 · 1
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Bisacodyl GR Tablets IP 5MG | Batch LMT240480Mfg Apr 2024 · Exp Mar 2026 | The sample does not conform to I.P.w.r.t. the test for Dissolution and AssayAssay | SDTL, AssamState lab | Feb 2026 |
| Albendazole Tablets IP 400mg | Batch LMT240917Mfg Aug 2024 · Exp Jan 2027 | The sample does not conform to the IP with respect to Assay and Dissolution.Assay | DTL, JaipurState lab | Oct 2025 |
| Ascorbic Acid Tablets IP 500 mg | Batch LMT240702Mfg Jun 2024 · Exp May 2026 | DescriptionDescription | Jammu and KashmirState lab | Aug 2025 |
| Albendazole Tablets 400 mg. | Batch LMT241013Mfg Sep 2024 · Exp Aug 2026 | The sample does not conform to IP w.r.to the tests for ? Dissolution? and ?Assay?Assay | Government Analyst,SDTL, Guwahati,AssamState lab | Jul 2025 |
| Zinc Sulphate Dispersible Tablets IP 20 mg | Batch LMT240804Mfg Jul 2024 · Exp Jun 2026 | Uniformity of Dispersion & DisintegrationDisintegration | RDTL, GuwahatiCDSCO lab | May 2025 |
| Losartan Potassium 50mg & Hydrochlorthiazide 12.5mg Tablets | Batch LMT251666Mfg Feb 2025 · Exp Jan 2027 | Dissolution Test: The Dissolution of Losartan Potassium and Hydrochlorthiazide does not complies within the Prescribed limit of not less than Q value i.e. 70% of labelled claim as stated in I.P 2022.Dissolution | State Drugs Laboratory, PunjabState lab | Apr 2025 |
| Levetiracetam Tablets IP 500 mg | Batch LMT241488Mfg Dec 2024 · Exp Nov 2026 | DissolutionDissolution | CDTL IndoreCDSCO lab | Apr 2025 |
| Albendazole Tablets IP 400 mg | Batch LMT241100Mfg Sep 2024 · Exp Aug 2026 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Apr 2025 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | Batch LMT240449Mfg Apr 2024 · Exp Mar 2026 | Dissolution (Calcium) and Assay of Vitamin D3Assay | RDTL, GuwahatiCDSCO lab | Mar 2025 |
| Albendazole Tablets IP 400 mg | Batch LMT241138Mfg Oct 2024 · Exp Sep 2026 | "Dissolution" of AlbendazoleDissolution | RDTL GuwahatiCDSCO lab | Feb 2025 |
| Zinc Sulphate Dispersible Tablets IP 20 mg | Batch LMT240811Mfg Jul 2024 · Exp Jun 2026 | Uniformity of dispersion & DisintegrationDisintegration | RDTL GuwahatiCDSCO lab | Jan 2025 |
| Losartan Tablets IP 50 mg | Batch LMT240826Mfg Jul 2024 · Exp Jun 2026 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Jan 2025 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | Batch LMT240431Mfg Apr 2024 · Exp Mar 2026 | Identification and Assay of Vitamin D3 and Dissolution of CalciumAssay | RDTL GuwahatiCDSCO lab | Jan 2025 |
| Zinc Sulphate Dispersible Tablets IP 20 mg | Batch LMT240811Mfg Jul 2024 · Exp Jun 2026 | Uniformity of dispersion & DisintegrationDisintegration | RDTL GuwahatiCDSCO lab | Dec 2024 |
| Glimepiride Tablets I.P. 1 mg | Batch LMT240339Mfg Mar 2024 · Exp Feb 2026 | Dissolution of GlimepirideDissolution | RDTL GuwahatiCDSCO lab | Dec 2024 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | Batch LMT240346Mfg Mar 2024 · Exp Feb 2026 | Assay of Vitamin D3 and Dissolution for calciumAssay | RDTL GuwahatiCDSCO lab | Dec 2024 |
| Telmisartan Tablets IP 40 mg | Batch LMT240520Mfg May 2024 · Exp Apr 2026 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Nov 2024 |
| Telmisartan Tablets I.P. 40 mg | Batch LMT240611Mfg May 2024 · Exp Apr 2026 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Nov 2024 |
| Telmisartan Tablets IP 40 mg | Batch LMT240536Mfg May 2024 · Exp Apr 2026 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Oct 2024 |
| Telmisartan Tablets I.P. 40 mg | Batch LMT240611Mfg May 2024 · Exp Apr 2026 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Oct 2024 |
| Glimepiride Tablets IP 2 mg | Batch LMT240333Mfg Mar 2024 · Exp Feb 2026 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Oct 2024 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | Batch LMT240377Mfg Mar 2024 · Exp Feb 2026 | Dissolution of Calcium and Assay of Vitamin D3Assay | RDTL GuwahatiCDSCO lab | Oct 2024 |
| Glimepiride Tablets IP 1 mg | Batch LMT240339Mfg Mar 2024 · Exp Feb 2026 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Sep 2024 |
| Glimepiride Tablets I.P. 2 mg | Batch LMT240157Mfg Feb 2024 · Exp Jan 2026 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Sep 2024 |
| Calcium 500 mg and Vitamin D3 250 IU Tablets IP | Batch LMT240025Mfg Jan 2024 · Exp Dec 2025 | Assay of Calcium and Vitamin D3 and Dissolution of CalciumAssay | RDTL GuwahatiCDSCO lab | Sep 2024 |
| Telmisartan Tablets IP 40 mg | Batch LMT240528Mfg May 2024 · Exp Apr 2026 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Aug 2024 |
| Telmisartan Tablets IP 40 mg | Batch LMT240502Mfg Apr 2024 · Exp Mar 2026 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Aug 2024 |
| Telmisartan Tablets IP 40 mg | Batch LMT240502Mfg Apr 2024 · Exp Mar 2026 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Aug 2024 |
| Olmesartan Medoxomil Tablets IP 40 mg | Batch LMT240387Mfg Mar 2024 · Exp Feb 2026 | Dissolution of Olmesartan MedoxomilDissolution | RDTL GuwahatiCDSCO lab | Aug 2024 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | Batch LMT231058Mfg Dec 2023 · Exp Nov 2025 | Assay of Calcium and vitamin D3 and Dissolution of CalciumAssay | RDTL GuwahatiCDSCO lab | Aug 2024 |
| Calcium 500 mg. with Vitamin D3 250 IU Tablets IP | Batch LMT240412Mfg Apr 2024 · Exp Mar 2026 | Dissolution (Calcium) and Assay of Vitamin D3Assay | RDTL GuwahatiCDSCO lab | Jul 2024 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | Batch LMT240376Mfg Mar 2024 · Exp Feb 2026 | Dissolution of Calcium & Assay of Vitamin D3Assay | RDTL GuwahatiCDSCO lab | Jul 2024 |
| Calcium 500 mg with Vitamin D3 250 IU Tablets IP | Batch LMT240335Mfg Mar 2024 · Exp Feb 2026 | Dissolution (Calcium) and Assay of Vitamin D3Assay | RDTL GuwahatiCDSCO lab | Jul 2024 |
| Calcium 500 mg and Vitamin D3 250 IU Tablets IP | Batch LMT240348Mfg Mar 2024 · Exp Feb 2026 | Dissolution of Calcium and Assay of vitamin D3Assay | RDTL GuwahatiCDSCO lab | Jul 2024 |
| Calcium 500 mg withVitaminD3250 IU Tablets IP | Batch LMT240 263Mfg Mar 2023 · Exp Feb 2026 | The sample Does not Complies conforms to I.P. with respect to the above tests only.Other | RDTL GuwahatiCDSCO lab | May 2024 |
| Zinc Sulphate Tablets 50 mg Zincload-50 | Batch LMT210773Mfg Aug 2021 · Exp Jul 2023 | DisintegrationDisintegration | RDTL GuwahatiState lab | Jan 2023 |
| Levocetirizine Dihydrochloride Tablets I.P. 5mg. | Batch LC18004Mfg Apr 2018 · Exp Mar 2020 | DissolutionDissolution | RDTL GuwahatiState lab | Nov 2019 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.